A Multicenter, Randomized Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of HMPL-306 in Patients With Gliomas Harboring IDH1 and/or IDH2 Mutations
Latest Information Update: 23 Jun 2025
At a glance
- Drugs Ranosidenib (Primary)
- Indications Glioma
- Focus Adverse reactions
- Sponsors HUTCHMED
Most Recent Events
- 23 Jun 2025 New trial record